JAK1 and neoplasm: A JAK1P1044S mutation affecting the activation loop of JAK1 that was detected in all 41 regions and conferred signaling hypomorphism by Ba/F3 mutant transformation assay (Fig. 1c) potentially contributed to the immunotherapy resistance displayed by this tumor clinically9.